CXCR4 and idiopathic pulmonary fibrosis: We therefore sought to define the short-term safety profile of sirolimus in patients with IPF, and we tested the hypothesis that short-term treatment with sirolimus reduces the number of circulating CXCR4+ fibrocytes in this population.